Download PDF
Z Gastroenterol 2014; 52(12): 1389-1393
DOI: 10.1055/s-0034-1366768
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Patients with Helicobacter pylori negative gastric marginal zone b-cell lymphoma (MZBCL) of MALT have a good prognosis

Patienten mit Helicobacter-pylori-negativen gastralen Marginalzonen-B-Zell-Lymphomen (MZBZL) des MALT haben eine gute Prognose
O. Al-Taie
2   Department of Internal Medicine II, Klinikum Aschaffenburg, Aschaffenburg, Germany
,
E. Al-Taie
2   Department of Internal Medicine II, Klinikum Aschaffenburg, Aschaffenburg, Germany
,
W. Fischbach
1   Department of Internal Medicine, Sankt Elisabeth Hospital, Guetersloh, Germany
› Author Affiliations
Further Information

Publication History

22 November 2013

15 June 2014

Publication Date:
04 December 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Background: In current guidelines H. pylori eradication is recommended as first-line therapy in patients with gastric MALT lymphoma irrespective of stage and H. pylori status. However, data on treatment and clinical course of patients with H. pylori negative MALT lymphoma are rare.

Aim: To evaluate therapeutical results in patients with H. pylori negative gastric MALT lymphoma.

Methods: 21 patients (13 male and 8 female; 63.9 years, range 43 – 80) with gastric MALT lymphoma were analysed retrospectively on the basis of medical reports in all cases and repeated outpatient visits at our center in 17 cases. H. pylori infection was excluded by negative histology, rapid urease test, or C13 urease breath test, and serology in all cases. Follow-up was 56.4 (5 – 142) months.

Results: Ten of 21 patients were treated with H. pylori eradication, and four of them received no further therapy. The other six patients underwent surgery, chemotherapy, and radiation, after eradication therapy. Those eleven patients without H. pylori eradication received radiation (n = 3), chemotherapy (n = 1), PPIs (n = 2), no treatment (n = 4) as first-line and radiation (n = 2) as second-line therapy while initial therapy remained unknown in one case. 13 patients (61.9 %) reached complete remission of lymphoma, and seven patients (33.3 %) showed minimal histological residuals. Overall and disease-free survival was found in 95 % and 90 %, respectively.

Conclusion: Patients with H. pylori negative gastric MALT lymphoma have a good prognosis. We favor initial H. pylori eradication therapy and a watch-and-wait strategy in case of minimal histological residuals of MALT lymphoma. Non-responders to eradication therapy can be successfully treated by radiation and chemotherapy.

Zusammenfassung

Hintergrund: In den bestehenden Leitlinien wird die H.-pylori-Eradikation als Erstlinientherapie bei Patienten mit gastralen MALT-Lymphomen unabhängig von Stadium und H.-pylori-Status empfohlen. Es existieren indessen nur spärliche Daten zur Behandlung und zum klinischen Verlauf von Patienten mit H.-pylori-negativen MALT-Lymphomen.

Ziel: Das Therapieansprechen bei Patienten mit H.-pylori-negativen gastralen MALT-Lymphomen.

Methode: 21 Patienten (13 Männer und 8 Frauen; mittleres Alter 63,9 Jahre, Alterspanne 43 – 80) mit gastralen MALT-Lymphomen wurden retrospektiv auf der Basis der Krankenunterlagen in allen Fällen und wiederholter ambulanter Untersuchungen in unserem Zentrum in 17 Fällen analysiert. Eine H.-pylori-Infektion war durch negative Histologie, Urease-Test oder 13C-Harnstoff-Atemtest und Serologie in allen Fällen ausgeschlossen. Der Beobachtungszeitraum betrug 56,4 (5 – 142) Monate.

Ergebnisse: Zehn von 21 Patienten wurden einer H.-pylori-Eradikation zugeführt; vier von ihnen erhielten keine weitere Therapie. Die anderen 6 Patienten wurden nach der Eradikation operiert oder mittels Chemotherapie oder Bestrahlung behandelt. Von den 11 Patienten ohne H.-pylori-Eradikation erhielten in der Erstlinienbehandlung 3 eine Bestrahlung, einer eine Chemotherapie, 2 PPIs und 4 blieben ohne jede Therapie. Zwei Patienten wurden in der Zweitlinie bestrahlt, in einem Fall blieb die initiale Therapie unbekannt. 13 Patienten (61,9 %) erreichten eine komplette Lymphomremission. Sieben Patienten (33,3 %) ließen nur minimale histologische Residuen des MALT-Lymphoms erkennen. Die Gesamtüberlebensrate betrug 95 %, das krankheitsfreie Überleben 90 %.

Schlussfolgerung: Patienten mit H.-pylori-negativen gastralen MALT-Lymphomen haben eine gute Prognose. Wir favorisieren eine initiale H.-pylori-Eradikation und eine zuwartende Haltung im Falle von nur minimalen histologischen Residuen des MALT-Lymphoms. Patienten, die auf die Eradikationsbehandlung nicht ansprechen, können erfolgreich mittels Bestrahlung und Chemotherapie behandelt werden.

Schlüsselwörter

MALT-Lymphom - Helicobacter pylori - Magen

Key words

MALT Lymphoma - Helicobacter pylori - Gastric
 

  • References

  • 1 Fischbach W. Gastric Mucosal-Associated Lymphoid Tissue Lymphoma. Gastroenterol Clin N Am 2013; 42: 371-380
    CrossrefPubMedGoogle Scholar
  • 2 Eck M, Schmaußer W, Haas R et al. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 1997; 112: 1482-1486
    CrossrefPubMedGoogle Scholar
  • 3 Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue. Lancet 1993; 342: 575-577
    CrossrefPubMedGoogle Scholar
  • 4 Zullo A, Hassan C, Cristofari F et al. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110
    CrossrefPubMedGoogle Scholar
  • 5 Fischbach W, Goebeler-Kolve ME, Dragosics B et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication: experience from a large prospective series. GUT 2004; 53: 34-37
    CrossrefPubMedGoogle Scholar
  • 6 Wündisch T, Dieckhoff P, Greene B et al. Second cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and Followed for 10 Years. Gastroenterology 2012; 143: 936-942
    CrossrefPubMedGoogle Scholar
  • 7 Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP et al. EGILS consensus report. Gastric extranodal marginal zone B cell lymphoma of MALT. Gut 2011; 60: 747-758
    CrossrefPubMedGoogle Scholar
  • 8 Raderer M, Streubel B, Wöhrer S et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616-618
    CrossrefPubMedGoogle Scholar
  • 9 Zullo A, Hassan C, Ridola L et al. Eradication Therapy in Helicobacter pylori-negative, Gastric Low-grade Mucosa-associated Lymphoid Tisseu Lymphoma Patients. A systematic Review. J Clin Gastroenterol 2013; DOI: 10.1097/MCG.0b013e318286ff72.
    PubMedGoogle Scholar
  • 10 Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapie 1977; 153: 218-221
    PubMedGoogle Scholar
  • 11 Radaszkiewicz Th, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue. Factors relevant to prognosis. Gastroenterology 1992; 102: 1628-1638
    PubMedGoogle Scholar
  • 12 Fischbach W, Goebeler-Kolve M, Starostik P et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002; 360: 547-548
    CrossrefPubMedGoogle Scholar
  • 13 Fischbach W, Goebeler ME, Ruskone-Fourmestraux A et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wait strategy. Experience from a large international series. Gut 2007; 56: 1685-1687
    CrossrefPubMedGoogle Scholar
  • 14 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline „helicobacter pylori and gastroduodenal ulcer disease“ of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e.V., German society for rheumatology, AWMF-registration-no. 021/001. Z Gastreoenterol 2009; 47 (12) 1230-1263
    PubMedGoogle Scholar
  • 15 Akamatsu T, Mochizuki T, Okiyama Y et al. Comparison of Localized Gastric Mucosa-Associated Lymphoid (MALT) Lymphoma with and without Helicobacter pylori Infection. Helicobacter 2006; 11: 86-95
    CrossrefPubMedGoogle Scholar
  • 16 Chung SJ, Kim JS, Kim H et al. Long-term clinical outcome of Helicobacter pylori-negative Gastric Mucosa-associated Lymphoid Tissue Lymphoma is Comparable to That of H. pylori-positive Lymphoma. J Clin Gastroenterol 2009; 43: 312-317
    CrossrefPubMedGoogle Scholar
  • 17 Park HS, Kim YJ, Yang WI et al. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010; 16 (17) 2158-2162
    CrossrefPubMedGoogle Scholar
  • 18 Chan CC, Shen D, Mochizuki M et al. Detection of Helicobacter pylori and Chlamydia pneumonia genes in primary orbital lymphoma. Trans Am Ophthalmol Soc 2006; 104: 62-70
    PubMedGoogle Scholar
  • 19 Lecuit M, Abachin E, Martin A et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239-248
    CrossrefPubMedGoogle Scholar
  • 20 Alibek K, Bekmurzayeva A, Mussabekova A et al. Using antimicrobial adjuvant therapy in cancer treatment: a review. Infectious Agents and Cancer 2012; 7: 33-42
    CrossrefPubMedGoogle Scholar
  • 21 Ishimatsu Y, Mukae H, Matsumoto K et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest 2010; 138: 730-733
    CrossrefPubMedGoogle Scholar
  • 22 Ferreri AJM. Activity of Clarithromycin in Mucosa-Associated Lymphoid Tissue-Type Lymphomas. Chest 2011; 139: 724-725
    PubMedGoogle Scholar